Steven Axon, chief executive of US-based Glycomine Inc has joined the board of Complement Therapeutics Ltd in the UK as an independent director. He will help support the company’s portfolio which is investigating therapies for complement-mediated diseases. The lead product is a gene therapy for macular degeneration.
Mr Axon was previously CEO of Prothelia Inc, a preclinical company focused on muscular dystrophy. He has both bachelor and master’s degrees in biomedical engineering from the University of Toronto in Canada.
Complement Therapeutics announced the appointment on 18 July 2022.
Copyright 2022 Evernow Publishing Ltd